Marcos Agramont reports
ISODIOL INTERNATIONAL ANNOUNCES U.S. SALES LAUNCH OF HOPS-DERIVED CBD PRODUCT, IMMUNAG
Isodiol International Inc. has launched U.S. sales of ImmunAG, the market's first non-cannabis cannabidiol (CBD) product derived from the hops plant. The time-released tablet will be unveiled at the Marijuana Business Conference and Expo (MJBizCon) in Las Vegas and available for purchase through Isodiol's website.
"The release of ImmunAG is a monumental milestone for Isodiol as it marks the industry's first foray into non-cannabis CBD products," said Marcos Agramont, chief executive officer of Isodiol. "This launch is a continuation of our company strategy to provide a diverse range of products as we strive to increase shareholder value by creating entirely new market segments."
Using proprietary extraction and purification methodologies, Isodiol is able to maintain the bioactivity (or a substance's effectiveness on a target) of the molecule at a level much greater than anything currently derived from the cannabis plant. The ImmunAG tablet does not dissolve in the stomach, but rather dissolves in the lower intestine, creating greater bioactivity.
"Cannabis is accepted by less than 10 per cent of the world, while the hops plant is accepted universally," said Mr. Agramont. "This significant expansion of the global marketplace, paired with our ability to manufacture and distribute the product worldwide, gives us access to practically every country and avails this product and subsequent products to the global marketplace."
The company will be exhibiting all its product offerings at booth No. 714 and No. 4,699 of MJBizCon from Nov. 15 to Nov. 17 in Las Vegas at the Marijuana Business Conference and Expo.
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical-grade and nutraceutical-grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd. All rights reserved.